RIDA®Jump Alliance
Aligned Automation for Your Next
High-Throughput Workflow
The RIDA®Jump Alliance combines semi-automated nucleic acid extraction with high-throughput Multiplex Tandem PCR (MT-PCR) to create a complete molecular diagnostic workflow for laboratories processing larger sample volumes. Integrating the RIDA®Xtract 96 with the RIDA®Jump platform, the Alliance streamlines sample preparation, PCR setup and result generation into a highly efficient workflow that reduces hands-on time while delivering reliable, reproducible molecular diagnostic results.
Features & Benefits
- Sample to result for 96 samples in approx. 4 hours and 45 minutes
- Separate sample purification and MT-PCR allows parallel batching for optimal productivity
- Automatic sample aliquoting
- Automatic barcode scanning for reduced hands-on time
- Easy setup; takes just a few minutes
High-Throughput Workflow Automation
The RIDA®Jump Alliance has been designed for laboratories requiring maximum throughput without compromising accuracy or consistency. By combining semi-automated nucleic acid purification with intelligent MT-PCR processing, the system supports continuous, high-volume testing while reducing manual intervention throughout the workflow. Separate extraction and PCR processes allow parallel batching to maximise laboratory productivity, while integrated barcode tracking and automated sample handling improve traceability, standardisation and overall operational efficiency.
RIDA®Jump
The RIDA®Jump is a high-throughput MT-PCR platform developed to automate complex molecular testing workflows while maintaining exceptional analytical performance. Capable of processing up to 96 samples in a single run, the system enables laboratories to detect multiple clinically relevant genetic targets simultaneously using R-Biopharm’s Multiplex Tandem PCR technology. Intelligent automation, precise liquid handling and integrated workflow management reduce hands-on time while supporting fast, accurate and reproducible diagnostic results across routine and high-demand laboratory environments.
As part of the RIDA®Jump Alliance, the system integrates seamlessly with the RIDA®Xtract 96, creating a streamlined workflow from semi-automated nucleic acid extraction through to MT-PCR analysis. Together, these technologies provide laboratories with a scalable solution that supports growing testing demands while maintaining efficiency, traceability and confidence in every result.
RIDA®Xtract 96 (Coming Soon)*
The RIDA®Xtract 96 provides semi-automated nucleic acid extraction for laboratories performing high-volume molecular diagnostics. Using proven magnetic bead technology, the system delivers high-quality DNA and RNA purification from a broad range of specimen types while minimising manual handling and workflow variability. Designed to process up to 96 samples in a single run, it provides the throughput, consistency and reliability required for modern diagnostic laboratories managing increasing testing demands.
Within the RIDA®Jump Alliance, the RIDA®Xtract 96 serves as the starting point of the automated workflow, preparing purified nucleic acids that are transferred efficiently to the RIDA®Jump platform for MT-PCR analysis. This integrated approach reduces bottlenecks, improves standardisation and enables laboratories to achieve faster turnaround times while maintaining consistently high extraction performance.
The Process
End-to-End High-Throughput Molecular Diagnostics
The RIDA®Jump Alliance delivers a complete molecular diagnostic workflow that combines semi-automated sample purification, high-throughput MT-PCR and intelligent laboratory automation into a single integrated solution. Designed for laboratories seeking to maximise efficiency without compromising diagnostic quality, the platform supports reliable, scalable molecular testing with minimal hands-on time. Backed by R-Biopharm Australia’s local expertise and trusted global technology, the RIDA®Jump Alliance enables laboratories to confidently meet growing testing demands while maintaining exceptional accuracy and reproducibility.
Systems are intended for in vitro diagnostics use by authorised clinical testing laboratories in Australia, New Zealand, Great Britain, and the European Economic Area, and are included on the Australian Register of Therapeutic Goods (ARTG), the MHRA database (REF: 10541) and compliant with the European Regulation (EU) 2017/746 . In the USA: For Research Use Only (RUO), not for use In diagnostic procedures.
